FDA Clears Momentis’ Anovo Robot for Multiport Surgery

Momentis Surgical has achieved U.S. Food and Drug Administration (FDA) 510(k) clearance for the multiport configuration of its Anovo surgical robotic system.

U.S. surgeons can now use Anovo’s internally articulated and human-inspired shoulder-, elbow-, and wrist-like robotic instruments in a typical multiport approach along with the same single-port/single-site core platform. There is now the option of either approach for ventral hernia repair, with the multiport option added to single-site and transvaginal approaches in gynecological surgery.

Momentis lauded the milestone of having the only robotic surgical platform that can support multiple surgical access strategies without needing to switch systems.

“From the beginning, our vision was never to build another robotic system that simply replicated laparoscopy,” said CEO Dvir Cohen. “We set out to rethink robotic surgery from the inside out. This clearance represents another important step toward that vision by giving surgeons the flexibility to choose the appropriate surgical approach for the patients’ benefit while using the same compact robotic platform.”

Conventional robotic systems generally rely on rigid, straight instruments that require larger external arm movements. Anovo uses internally articulated instruments that move the point of articulation inside the patient, reducing external arm movement while providing 360-degree articulation at the surgical site. The company said the approach is designed to support a more compact robotic system.

“The future of robotic surgery will not be defined by a single access technique,” said Maurice R Ferré, MD, Momentis Chairman, Insightec Chirman and CEO, and co-founder and former CEO of MAKO Surgical. “Surgeons need the flexibility to select the best approach for each patient. With this clearance, Anovo becomes a truly adaptable platform capable of supporting natural orifice, single-port, and multiport procedures within one unified robotic ecosystem.” Until now, hospitals have largely had to choose robotic systems based on surgical approach. This clearance provides the modularity of natural orifice, single-site, and multiport surgery for the indicated procedures on a single flexible robotic platform.

In November 2024, the company won the first FDA de novo authorization for a robotic transvaginal surgical system.